|
LYMErix® Pregnancy Registry for LYMErix® Lyme Disease Vaccine (Recombinant OspA) To participate in this registry: Registration should take place as early in the pregnancy as possible and prior to any knowledge of the pregnancy outcome. Healthcare providers are encouraged to notify the registry staff of ongoing pregnancies where exposure to the vaccine has already occurred. Patients can be registered by calling GlaxoSmithKline directly at 1-888-825-5249 (toll-free). GlaxoSmithKline's LYMErix® Pregnancy Registry is managed at:
LYMErix® Pregnancy Registry Information collected at the time of registration includes date(s) of vaccine exposure, estimated date of delivery, and sufficient contact information to allow for follow-up of the subsequent pregnancy outcome. Measures are in place to protect patient confidentiality. If Registration is initiated from a consumer, permission is requested to obtain confirmation and follow-up from their health care provider. Around the patient’s estimated date of delivery, a short follow-up form is sent to the registering healthcare provider to report on the pregnancy course and outcome. Additional resources: |
|